|Day Low/High||85.92 / 87.38|
|52 Wk Low/High||74.97 / 96.31|
We think the quarter will gain the proper recognition as time progresses.
Novartis beats analysts' third-quarter earnings expectations on a double-digit increase in sales.
Our focus today is on Novartis, Caterpillar, Microsoft and Lam Research.
Jim discusses trade with China, what to think of Novartis before tomorrow morning's earnings release, an Apple price target increase at Raymond James and more!
Let's circle back to last Friday's stock-driving headlines.
This discounted value and the potential benefits of the merger/integration catalyst is why we continue view this stock as a hold despite its recent struggles.
This strong beat and raise result should spark renewed buying interest in the stock.
It is disheartening to see a new litigation headline pop up, but we do not expect this risk to have the staying power of talc and opioids.
A volatile week ends with heightened expectations for at least one more rate cut from the Fed.
Breadth was crummy, the Russell lagged and the number of stocks making new lows on a 10-day moving average shows no sign of turning down yet.
The ADP numbers... are beginning to show signs of a slowdown as employers grow more cautious when it comes to hiring activity.
With the market expected to continue Tuesday's weak ISM PMI-driven woes, we are in position to do some buying at newly discounted prices.
Markets buffeted by impeachment turmoil and shift away from high-multiple growth names.
Jim talks about his interview with Twilio CEO Jeff Lawson, Facebook amid the DoJ's antitrust probe and answers a club member's question!
Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.
Markets traded mostly flat this week in spite of Saudi oil attacks, and a Fed rate cut, only turning sour on Friday on signs of renewed U.S. trade tensions with China.
We want to nibble on Novartis, which is barely reacting to company-specific positive news.
Jim Cramer says investors need to stay vigilant, despite recent market gains. He's got your game plan for next week.
Jim Cramer takes a look at Trex, Enphase Energy, Alcon, Rite Aid, Tallgrass Energy and more.
Easing trade tensions and steepening yield curve add to bulls' optimism.
We will buy more Novartis shares and trim our Lam Research position.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.